Onco Actu du 17 décembre 2015

	1. Biologie
Lung cancer found to be genetically different disease in young and older patients [Dana-Farber Cancer Institute] In a study published online today by JAMA Oncology, investigators scanned the DNA of thousands of NSCLC tumor samples for abnormalities and found that younger patients were more apt to have genetic subtypes of the disease that can be treated with available targeted therapies.
	2. Etiologie
Does Cycling Increase Risk for Testicular or Prostate Cancer? [Dana-Farber Cancer Institute] Since professional cyclist Lance Armstrong was diagnosed with testicular cancer in 1996, many men have wondered about the connection between cycling and testicular cancer, as well as prostate cancer. While a number of studies have looked into a link between the sport and cancer, the findings to date are inconclusive, says Mark Pomerantz, MD.
	4.11 Dép., diag. & prono. - Ovaire
Ovarian cancer screening trial – a tantalising result? [Cancer Research UK] We don’t think there’s enough evidence for the NHS to introduce a national screening programme at this stage. We don’t recommend women use a privately available ovarian cancer blood test.
Screening women for ovarian cancer shows first success [STAT] The women were randomly assigned to one of three groups: annual transvaginal ultrasound, which tries to detect suspicious masses; an annual blood test for CA-125 plus ultrasound; or no screening.At first blush, it seemed that screening failed again...
Groundbreaking Trial Reports Positive Results on Screening for Ovarian Cancer [ACS] Dr. Ian Jacobs and colleagues studied approximately 200,000 women over more than a decade to determine whether multi-modal screening (MMS) with a “risk of ovarian cancer algorithm” (ROCA), a quantitative algorithm based on age, risk status and CA-125 levels over time, was effective in reducing ovarian cancer mortality compared with ultrasound alone or usual care.
Ovarian cancer: Screening may cut deaths by a fifth [BBC News] The results are now in, but the interpretation is a bit messy and the researchers admit it is "controversial".
Early Detection of Ovarian Cancer May Become Possible [NY Times] Her reason for caution was that the study passed only two of three tests of statistical significance, which means that the apparent benefits of screening might have been due to chance. She said a few more years of monitoring the participants would resolve that question.
Screening could prevent one in five ovarian cancer deaths, study shows [The Telegraph] “Finally we have data which suggests that screening may prevent ovarian cancer deaths,” said Professor Usha Menon, of UCL Women’s Health department, who co-led the trial.
	4.2 Dép., diag. & prono. - Génome
Responsible, proportionate data sharing for better and safer genetic services [PHG Foundation] Our joint publication with the Association of Clinical Genetic Science (ACGS) examines the most pressing challenges to achieving greater levels of data sharing within the NHS in the context of clinical genetics and genomics services.
	5.2 Pharma
Ariad Said to Name Panayiotopoulos CEO After Activist Push [Bloomberg Business] Ariad Pharmaceuticals Inc., a developer of blood and lung-cancer treatments, is set to name Paris Panayiotopoulos as chief executive officer, people familiar with the matter said. The move comes eight months after activist investor Alex Denner successfully pushed for the ouster of CEO Harvey Berger, the founder of the company.
	5.2.2 Pharma - Fusions & Acquisitions
AstraZeneca bets $7B on Acerta's potential blockbuster cancer treatment [FierceBiotech] The deal, expected to close in the first quarter of 2016, gives AstraZeneca an asset that management believes could bring in $5 billion a year at its peak. Acalabrutinib is a so-called BTK inhibitor, designed to interrupt the signaling process that B-cell cancers use to proliferate.
AstraZeneca Is Buying a Majority Stake in Acerta Pharma for $4 Billion [TheStreet] Acerta's acalabrutinib is being tested as a treatment for various types of leukemia, lymphoma and other cancers. The New England Journal of Medicine recently published positive results of early clinical testing of the drug, which is seen as a rival to Johnson & Johnson and AbbVie's Imbruvica and as a potential blockbuster treatment.
	5.4 Traitements - Economie
Five Years of Cancer Drug Approvals: Pricing, Novelty and Improvement [RAPS] Mark Shapiro, vice president of clinical development at contract research organization Clinipace, considers a recent JAMA study on cancer drug pricing.
Five Years of Cancer Drug Approvals: Most Cost Too Much and Give Us Too Little [RAPS] Mr. Shapiro may be correct that some novel drugs are taken for far less than a year. He doesn’t comment on the fact that this is a testament to just how marginal they are.
	5.5 ASCO
Bruce E. Johnson, MD, FASCO, Elected ASCO President for 2017-2018 Term [ASCO] An active ASCO member since 1986, Dr. Johnson is Chief Clinical Research Officer and Institute Physician at the Dana-Farber Cancer Institute and a Professor of Medicine at Harvard Medical School; and the Director of the Dana-Farber/Harvard Cancer Center (DF/HCC) Lung Cancer Program.
	5.6 ESMO
ESMO Asia 2015 Press Release: Immunotherapy and targeted therapy provide new options for difficult-to-treat head and neck cancer [ESMO] Phase I trial reports that pembrolizumab is active in nasopharyngeal cancer. Afatinib is effective as second-line treatment in squamous cell carcinoma of the head and neck in a Phase II study.
	5.7 SABCS
Mastectomy vs. lumpectomy: stories needed more context [HealthNewsReview] There’s always room for improvement, and some outlets glossed over key limitations, failed to address cost, and didn’t give readers a complete portrait of the harms associated with each approach. Hopefully this review will help journalists provide that much-needed context to stories filed at their next conference.
	6.7.3 DMP
Patients' Online Access To Records Welcomed [British Medical Association] The Wales Government has also said patients would be able to have 'virtual' consultations with clinicians either through email or online video conferencing.